Why is MPLT up?
Up 11% on Nov 6 while the S&P 500 rose 0.3%.
- MapLight Therapeutics rose 11% that day while biotech stocks rose a median 4%:
The timeline and its peers, for Pro members.
MapLight Therapeutics (MPLT) stock
$6.93
Quality Score
-7
In its industry
#253of 281
Checks firing
2of 14
From 52-week high
-82.9%
MPLT's Quality Score rose 2 points on Fri, Nov 6, to -7. It closed near its high of the day (2 chart checks started).
Follow MPLT's trial news. Pro members can get an alert when MapLight Therapeutics files news, and see its trials, share raises, and its CEO's filings.
Get an alert when MPLT files news on its trialsSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Next2H 2027“ongoing in the Phase 2 VISTA trial and topline results expected in the second half of 2027”
Cash$351M, about 8 quarters (2 years) at the last year's spending
Key facts on MPLT
| Holding it back | Moves 9.2% a day with no profit behind it |
| Latest filing | S-1, Sep 9 |
1 more reason behind MPLT's -7, free with an account →3 more reasons behind MPLT's -7, for Pro members.
MPLT in the news
ReportExpected to report Thursday, after the close. Every 3 months, a company tells everyone how much it sold and earned. It rose after 3 of its last 4 reports, +3.5% on average. Past reports ›
Cash$351M, about 8 quarters (2 years) at the last year's spending
MPLT catalysts
Coming up
After its last 4 reports it closed +3.5% on average, higher 3 of 4 times.
What's next for MPLT, and how long its cash lasts
Next step the company has named
2H 2027“ongoing in the Phase 2 VISTA trial and topline results expected in the second half of 2027”
Cash runway
About 8 quarters
Dilution on the horizon
No shelf registration or at-the-market program on file in the last three years.
Insiders
Chief Discovery Officer Anatol Kreitzer sold 12,248 shares on Oct 15. 41 more insider trades this year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Why MPLT scores -7
Poorfor quality, not price, 2 of 14 chart checks firingWhat the Quality Score means
- +2Chart checks 2 of 14 firing right now, one point each
- −3Insider trades the CEO is selling into the 52-week low: Christopher A. Kroeger (Chief Executive Officer) sold $595K on Oct 15, and 6 more filings
- Long-term trend subtracts
- Profit subtracts
- Volatility subtracts
- Cash flow subtracts
What every line is worth, and the reason behind it, on MPLT and every other stock.Get in free →
How MPLT ranks in Biotech
MPLT is #253 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 253 |
When does MPLT report earnings, and what happens after?
Expected to report Thu Nov 12, after the close (in 3 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
What MPLT reported on Aug 13, 2026
The quarter
The figures are not read from the release yet.
“R&D expenses increased primarily due to increases in clinical trial expenses and employee-related expenses, including an increase in stock-based compensation expense of $5.6 million.”
Where the sales came from
MPLT's results filing gives no sales by line in a table we read.
The outlook
No outlook figures read from this release.
In the company's words
“G&A expenses increased primarily due to increases in employee-related expenses, including an increase in stock-based compensation expense of $2.9 million, and increases in professional fees and other expenses.”
From its results filing (SEC filing · Aug 13)
The numbers
- $346M
- today
- -$175M
- last 12 months
Close after the report, last 3
+6.0%-1.9%+1.5%
Mar 26May 14Aug 13
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Aug 13, 2026 | +4.0% | +1.5% | -3.0% |
| May 14, 2026 | -2.8% | -1.9% | -0.0% |
| Mar 26, 2026 | -2.9% | +6.0% | +14.8% |
MPLT has 2 of 14 chart checks firing
The other 10 checks on MPLT, and all 14 on every stock.Get in free →
MPLT RSI on Nov 6: 34.6, below its 50-day and 200-day averages
RSI 34.6, MACD above signal, below both averages. Not scored.
The deep dive on MPLT
- What it does and how it makes money
- Where it standsSEC filing · Oct 27, 2025
- Who holds and trades it
MPLT insider trades
2 insiders bought $65.5M across 6 filings, and 6 insiders sold $7.8M across 27 filings, in the last 6 months. The newest:
SellChristopher A. Kroeger$595K
MPLT's officers and directors
Officers and directors with a Form 4 in the last 12 months.
Which ETFs hold MPLT?
In ETFs: MPLT is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
About MapLight Therapeutics
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
Listed on Nasdaq on Oct 27, 2025, and is 59% below its $17 offer price now. The offer price is from Massive's IPO calendar.
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
Pro members see every line of every stock's score.
- What would turn MPLT's score around: 7 things
- 3 more filings explained, a plain line each
- Real-time prices, no delay
BreakawayAug 18Catalyst4, Inc. bought MPLT
Straight AnswersStraight Answers
What does MPLT's Quality Score say?
MPLT scores -7 today, which Breakaway calls Poor. It is #253 of 281 in Biotech by Quality Score, with 2 of 14 chart checks firing. Up 11% on Nov 6 while the S&P 500 rose 0.3%. Cash lasts about 8 quarters at its spending (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
What is MPLT's Quality Score?
MPLT scores -7 today, which Breakaway calls Poor (below zero). That is #253 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind MPLT's -7.
Are insiders buying MPLT?
2 insiders bought $65.5M across 6 filings, and 6 insiders sold $7.8M across 27 filings, in the last 6 months. The newest is Christopher A. Kroeger, Chief Executive Officer, who sold $595K on Oct 15. Every filing, with the scored weight, for Pro members.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.